StageZero Life Sciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
James Howard-Tripp
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 8.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | no data |
| Board average tenure | 16.4yrs |
Recent management updates
CEO
James Howard-Tripp
8.2yrs
Tenure
US$270,000
Compensation
Mr. James R. Howard-Tripp has been the Executive Chairman of StageZero Life Sciences Ltd. (formerly known as GeneNews Limited) (also known as ChondroGene Ltd.) since July 12, 2013 and has been its Chief Ex...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 22.8yrs | US$270.00k | 0.19% CA$ 9.3k | |
| Independent Director | 24.8yrs | US$40.00k | 10.15% CA$ 501.7k | |
| Independent Director | 24.4yrs | US$40.00k | 0.12% CA$ 5.9k | |
| Member of Colorectal Cancer Clinical Advisory Board | 15.9yrs | no data | no data | |
| Member of Colorectal Cancer Clinical Advisory Board | no data | no data | no data | |
| Member of Colorectal Cancer Clinical Advisory Board | 15.9yrs | no data | no data | |
| Independent Director | 16.4yrs | US$40.00k | 0.087% CA$ 4.3k | |
| Member of Colorectal Cancer Clinical Advisory Board | no data | no data | no data | |
| Chairman of Colorectal Cancer Clinical Advisory Board | 17.3yrs | no data | no data | |
| Member of Colorectal Cancer Clinical Advisory Board | no data | no data | no data | |
| Member of Colorectal Cancer Clinical Advisory Board | 15.9yrs | no data | no data | |
| Member of Colorectal Cancer Clinical Advisory Board | 15.9yrs | no data | no data |
16.4yrs
Average Tenure
71yo
Average Age
Experienced Board: SZLS's board of directors are seasoned and experienced ( 16.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/11 19:43 |
| End of Day Share Price | 2024/07/15 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
StageZero Life Sciences Ltd. is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Douglas Loe | Cantor Fitzgerald Canada Corporation |
| Chris Thompson | eResearch Corporation |
| Claude Camiré | Paradigm Capital, Inc. |